SEC Tracker
Get the app

Foghorn Therapeutics FHTX

Foghorn Therapeutics Q3 FY23: revenue $17.5M; diluted EPS −$0.34

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Foghorn Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$17.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$14.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.34No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$70.3MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$27.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Foghorn Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Omeros OMER public float $172M, Jun 30, 2025
  2. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  5. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.